Roberto Mallone (Cochin Institute) IBCS seminar - From benign islet autoimmunity to type 1 diabetes: lessons from the T-cell/beta-cell cross-talk
Online IBCS seminar - Roberto Mallone
IBCS seminar 28th April hosted by Professor Sarah Richardson
An Institute of Biomedical and Clinical Science seminar | |
---|---|
Date | 28 April 2021 |
Time | 15:00 to 16:30 |
Place | Zoom |
Event details
Abstract
Abstract
Recent evidence from our group and others suggest that we are all autoimmune, to a much larger extent than previously appreciated. This is due to a marginal deletion of autoreactive CD8+ T cells in the thymus. The key question is now to understand how this ‘benign’ islet autoimmunity can progress to type 1 diabetes in few individuals, and not in many others. Some hypotheses under scrutiny will be presented.
Link to event:
https://Universityofexeter.zoom.us/j/93399065773?pwd=RFZuVktKUGw1MlFYc2tRLy9UZFp6QT09
Meeting ID: 933 9906 5773
Password: 261489
Bio
Professor Mallone received his MD PhD degree from the University of Turin, Italy. After a Postdoc with Jerry Nepom at the Benaroya Institute in Seattle, he moved to Paris where he is currently Professor of Immunology at Paris Descartes University, Diabetologist at the Cochin Hospital and leads a research team at the INSERM Cochin Institute. His research focuses on autoimmune T cells and the understanding of type 1 diabetes mechanisms in order to develop T-cell-based biomarkers and therapeutics. Major contributions to the field include the isolation of islet-reactive CD4+ T cells from the blood of T1D patients, the demonstration of the central role of CD8+ T cells in beta-cell autoimmunity, the development of T-cell monitoring tools to clarify therapeutic mechanisms in clinical trials, and the exploration of perinatal vaccination strategies to improve thymic immune tolerance mechanisms. More recently, he described a universal state of ‘benign’ islet autoimmunity imprinted in the thymus (Sci Immunol 2018) and the first immunopeptidome of human beta cells (Cell Metab 2018).